Voleon Capital Management LP Buys 19,188 Shares of DexCom, Inc. $DXCM

Key Points

• Voleon Capital Management LP increased its stake in DexCom, Inc. by 33.1% in the first quarter, acquiring an additional 19,188 shares, bringing its total holdings to 77,110 shares valued at approximately $5.27 million.
• Several other institutional investors have also increased their positions in DexCom, with notable stakes raised by Golden State Wealth Management and Private Trust Co., contributing to institutional ownership rising to 97.75% of the company's stock.
• DexCom reported a quarterly EPS of $0.48, beating analysts' estimates, with a revenue increase of 15.2% year-over-year, and analysts have set an average price target of $99.89 for the stock.

Voleon Capital Management LP raised its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 33.1% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 77,110 shares of the medical device company's stock after buying an additional 19,188 shares during the period. Voleon Capital Management LP's holdings in DexCom were worth $5,266,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Brighton Jones LLC increased its stake in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after buying an additional 11,946 shares during the last quarter. Bank Pictet & Cie Europe AG increased its stake in shares of DexCom by 1.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock worth $8,637,000 after purchasing an additional 2,010 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of DexCom by 22.1% during the 4th quarter. Captrust Financial Advisors now owns 28,152 shares of the medical device company's stock worth $2,189,000 after purchasing an additional 5,101 shares during the last quarter. Brevan Howard Capital Management LP purchased a new stake in shares of DexCom during the 4th quarter worth approximately $261,000. Finally, Cetera Investment Advisers increased its stake in shares of DexCom by 16.8% during the 4th quarter. Cetera Investment Advisers now owns 72,182 shares of the medical device company's stock worth $5,614,000 after purchasing an additional 10,385 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

DexCom Stock Performance

DexCom stock traded up $0.22 during mid-day trading on Friday, reaching $76.22. The company's stock had a trading volume of 3,054,556 shares, compared to its average volume of 3,987,928. The firm's fifty day moving average price is $80.88 and its two-hundred day moving average price is $78.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The company has a market capitalization of $29.89 billion, a P/E ratio of 52.93, a PEG ratio of 1.59 and a beta of 1.48.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period last year, the firm earned $0.43 EPS. The business's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Sell-side analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, Director Mark G. Foletta sold 2,750 shares of the firm's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the completion of the transaction, the director directly owned 51,121 shares of the company's stock, valued at $4,143,868.26. This trade represents a 5.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the completion of the transaction, the executive vice president directly owned 106,689 shares of the company's stock, valued at approximately $9,494,254.11. The trade was a 1.36% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,237 shares of company stock worth $1,263,480. 0.32% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on DXCM. Argus began coverage on shares of DexCom in a research note on Thursday, August 21st. They set a "buy" rating and a $100.00 price target for the company. UBS Group raised their price target on shares of DexCom from $105.00 to $106.00 and gave the stock a "buy" rating in a research note on Thursday, July 31st. Truist Financial began coverage on shares of DexCom in a research note on Monday, June 16th. They set a "buy" rating and a $102.00 price target for the company. Oppenheimer lowered shares of DexCom from an "outperform" rating to a "market perform" rating in a research note on Monday, September 8th. Finally, Raymond James Financial raised their price target on shares of DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research note on Thursday, July 31st. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.